 Pyrroles
"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 1996 | 1 | 1 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 1 | 3 | | 2002 | 3 | 1 | 4 | | 2003 | 3 | 1 | 4 | | 2004 | 4 | 4 | 8 | | 2005 | 8 | 2 | 10 | | 2006 | 2 | 2 | 4 | | 2007 | 6 | 4 | 10 | | 2008 | 3 | 3 | 6 | | 2009 | 9 | 3 | 12 | | 2010 | 2 | 2 | 4 | | 2011 | 4 | 3 | 7 | | 2012 | 5 | 5 | 10 | | 2013 | 5 | 2 | 7 | | 2014 | 2 | 6 | 8 | | 2015 | 6 | 3 | 9 | | 2016 | 2 | 0 | 2 | | 2017 | 2 | 4 | 6 | | 2018 | 2 | 3 | 5 | | 2019 | 2 | 3 | 5 | | 2020 | 0 | 2 | 2 | | 2021 | 2 | 3 | 5 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
Rachubinski AL, Wallace E, Gurnee E, Enriquez-Estrada BA, Worek KR, Smith KP, Araya P, Waugh KA, Granrath RE, Britton E, Lyford HR, Donovan MG, Eduthan NP, Hill AA, Martin B, Sullivan KD, Patel L, Fidler DJ, Galbraith MD, Dunnick CA, Norris DA, Espinosa JM. JAK inhibition decreases the autoimmune burden in Down syndrome. Elife. 2024 Dec 31; 13.
-
Signoretti C, Matsumura S, Fatehi S, D'Silva M, Mathew R, Cendali F, D'Alessandro A, Alam SMS, Garcia V, Miano JM, Gupte SA. G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease. J Am Heart Assoc. 2024 Oct; 13(19):e035174.
-
Miller C, Sommavilla R, O'Bryant CL, Barve M, Dowlati A, Luke JJ, Khatun M, Morris T, Cullberg M. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Aug; 94(2):223-235.
-
Stewart KL, Szczesniak R, Liou TG. Predicting weight gain in patients with cystic fibrosis on triple combination modulator. Pediatr Pulmonol. 2024 Jun; 59(6):1724-1730.
-
Duong JT, Pope CE, Hayden HS, Miller C, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Hoffman LR, Narkewicz MR, Green N. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2024 May; 23(3):490-498.
-
Geng H, Lupton EJ, Ma Y, Sun R, Grigsby CL, Brachi G, Li X, Zhou K, Stuckey DJ, Stevens MM. Hybrid Polypyrrole and Polydopamine Nanosheets for Precise Raman/Photoacoustic Imaging and Photothermal Therapy. Adv Healthc Mater. 2023 10; 12(27):e2301148.
-
Alegret N, Dominguez-Alfaro A, Mecerreyes D, Prato M, Mestroni L, Pe?a B. Neonatal rat ventricular myocytes interfacing conductive polymers and carbon nanotubes. Cell Biol Toxicol. 2023 08; 39(4):1627-1639.
-
Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
DeAngelo DJ, Radia DH, George TI, Robinson WA, Quiery AT, Drummond MW, Bose P, Hexner EO, Winton EF, Horny HP, Tugnait M, Schmidt-Kittler O, Evans EK, Lin HM, Mar BG, Verstovsek S, Deininger MW, Gotlib J. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021 12; 27(12):2183-2191.
-
Kibbie J, Kines K, Norris D, Dunnick CA. Oral tofacitinib for the treatment of alopecia areata in pediatric patients. Pediatr Dermatol. 2022 Jan; 39(1):31-34.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|